Federal Antimonopoly Service of Russia agreed on the price of Vismodegib-Promomed, a Russian medicine for skin cancer treatment

The Federal Antimonopoly Service (FAS) of Russia has agreed on the prices of Vismodegib-Promomed, a domestic medicinal product developed by Promomed Group for treatment of basal cell carcinoma (basalioma), a type of skin cancer.

Vismodegib-Promomed will cost 40% less than its foreign originator. Such cost will increase availability of this medicine for Russian patients upon expiration of the patent for the original medical product and launch of the Russian generic equivalent. Patients will be provided with this medicine for free at the expense of budgetary funds under the program of state guarantees of free medical care.

Surgical removal and radiation therapy for many years have been the main treatments for basaloma. Vismodegib prevents the uncontrolled division and spread of cancer cells, which makes it possible to slow down or stop tumor extension. The benefits for patients include minimized surgical intervention, reduced potential health risks and improved quality of life.

Promomed Group has developed a full-cycle production process for Vismodegib-Promomed, from the pharmaceutical substance to the finished dosage form. The Group’s production capabilities make it possible to fully meet the demand in Russia.